(MENAFN – Investor Brand Network) Soligenix (NASDAQ: SNGX) announced that new supportive trial data for HyBryte(TM) in the treatment of cutaneous T-cell lymphoma will be presented at the United. ..
Biomednewsbreaks – Soligenix Inc. (NASDAQ: SNGX) Hybryte Data To Be Presented At USCLC Workshop Ahead Of AAD Meeting
RELATED ARTICLES



